Connected care enters a vital security frontier

Tern plc

As hospitals deploy more connected devices, the real vulnerability is no longer the network but the devices themselves. Device Authority is targeting this exact gap, offering a way to manage trust, identity and compliance at scale, all without manual oversight.

At the heart of the offering is automation of device trust and lifecycle management. For manufacturers and operators of connected medical equipment, the challenge lies in provisioning, rotating, revoking and monitoring credentials across large fleets, often in highly regulated settings. The KeyScaler platform is branded as delivering exactly that: seamless device registration, certificate management, enforcing Zero Trust policy at the edge, and continuous assurance of connected devices. By automating those security operations, the firm aims to reduce human error, accelerate incident response and support compliance across healthcare networks.

The company’s positioning in IoMT complements its broader IoT/OT play, suggesting opportunity for cross‑industry efficiencies. With connected medical devices trending upwards, and hospital networks under increasing pressure to secure them against threat actors and compliance breaches, the addressable market is set to expand.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search